Q3 2024 Earnings Call Transcript November 6, 2024 American Electric Power Company, Inc. beats earnings expectations. Reported ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, greetings, and welcome to the Pagaya 3Q ...

Union Pacific boasts strong operations and 18 years of dividend growth. Learn why UNP stock is a cornerstone of my portfolio ...

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025– Long-term azetukalner results from X-TOLE open-label ...

Forward-looking statements speak only as of the date on which they are made and except as required ... comparison to the prior periods is obviously impacted by the fact that American Coastal did not ...

Applied Therapeutics, Inc. (Nasdaq: APLT) (the“Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

As a result, it’s unsurprising that the shares have gained a modest 13.9% year to date. In fact, if it weren ... team and ...

Nav1.7 is an important pain-related target, based on strong human genetic validation, that may represent a new class of medicines without the limitations of opioids. The Company expects to nominate a ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update ...